BioCryst Q3 2026 slides: HAE portfolio drives 70% profit jump
BioCryst Pharmaceuticals (BCRX) reported Q3 2026 non-GAAP operating profit of $87M, up 70% YoY, driven by ORLADEYO revenue of $175M. The company raised full-year 2026 revenue guidance to $715M-$730M. ORLADEYO showed 91% reduction in monthly attack rate for HAE patients. Navenibart, a potential second HAE treatment, is in Phase 3 trials with data expected in Q3 2027. BioCryst also highlighted its pipeline, including BCX17725 for Netherton syndrome.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest near‑term upside for the stock, while pipeline milestones remain key.
Market read
First‑report earnings with raised guidance provide a fresh catalyst for BCRX and may lift the rare‑disease biotech sector.
What to watch
Potential regulatory hurdles for navenibart and cash burn from facility closure could temper upside.
Background
BioCryst presented its Q3 2026 earnings, highlighting a 70% profit jump and raising full‑year revenue guidance.
Ticker impact
Q3 2026 results show 70% profit increase and raised full-year revenue guidance to $715M-$730M.
upward pressure as market prices in higher earnings and guidance
Operating profit rose sharply and revenue outlook was lifted, prompting a 1.7% share rise after the presentation.
Market effects
Rare‑disease biotech sector may see broader optimism on profit growth and pipeline expansion.
U.S. biotech indices could gain modestly as BCRX lifts guidance.
Limited to investors focused on specialty pharma and rare‑disease pipelines.
Counterpoint
Guidance may be overly optimistic if pipeline delays occur, risking a pull‑back.
Key entities
- companyBioCryst Pharmaceuticals
NASDAQ‑listed rare‑disease biotech.
- productNavenibart
Long‑acting monoclonal antibody in Phase 3 for HAE.
